SG11201907422RA - Anti-tau antibodies and methods of use thereof - Google Patents

Anti-tau antibodies and methods of use thereof

Info

Publication number
SG11201907422RA
SG11201907422RA SG11201907422RA SG11201907422RA SG11201907422RA SG 11201907422R A SG11201907422R A SG 11201907422RA SG 11201907422R A SG11201907422R A SG 11201907422RA SG 11201907422R A SG11201907422R A SG 11201907422RA SG 11201907422R A SG11201907422R A SG 11201907422RA
Authority
SG
Singapore
Prior art keywords
therapeutics
floor
denali
south san
california
Prior art date
Application number
SG11201907422RA
Other languages
English (en)
Inventor
Xiaocheng Chen
Mark S Dennis
Lesley Ann Kane
Do Jin Kim
Joseph W Lewcock
Suresh Poda
Rishi Rakhit
Rinkan Shukla
Adam P Silverman
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of SG11201907422RA publication Critical patent/SG11201907422RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201907422RA 2017-02-17 2018-02-15 Anti-tau antibodies and methods of use thereof SG11201907422RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762460642P 2017-02-17 2017-02-17
US201762583400P 2017-11-08 2017-11-08
PCT/US2018/018415 WO2018152359A1 (fr) 2017-02-17 2018-02-15 Anticorps anti-tau et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
SG11201907422RA true SG11201907422RA (en) 2019-09-27

Family

ID=61563475

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907422RA SG11201907422RA (en) 2017-02-17 2018-02-15 Anti-tau antibodies and methods of use thereof

Country Status (14)

Country Link
US (1) US11370832B2 (fr)
EP (1) EP3583123A1 (fr)
JP (1) JP2020508054A (fr)
KR (1) KR20190134997A (fr)
CN (1) CN110520440A (fr)
AU (1) AU2018221049A1 (fr)
BR (1) BR112019017021A2 (fr)
CA (1) CA3053379A1 (fr)
IL (1) IL268658A (fr)
MA (1) MA47499A (fr)
MX (1) MX2019009817A (fr)
SG (1) SG11201907422RA (fr)
TW (1) TW201843175A (fr)
WO (1) WO2018152359A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201506244VA (en) 2013-03-13 2015-09-29 Prothena Biosciences Ltd Tau immunotherapy
BR112018072389A2 (pt) 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem tau
DK3452507T3 (da) 2016-05-02 2022-11-14 Prothena Biosciences Ltd Tau-immunoterapi
PT3583120T (pt) 2017-02-17 2022-12-15 Denali Therapeutics Inc Polipeptídeos de ligação ao recetor de transferrina manipulados
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
EP3692070A1 (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc. Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
KR102225178B1 (ko) * 2017-10-16 2021-03-10 에자이 알앤드디 매니지먼트 가부시키가이샤 항-타우 항체 및 그의 용도
WO2019094608A1 (fr) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anticorps anti-bace1 et leurs procédés d'utilisation
WO2019094576A1 (fr) * 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anticorps bispécifiques bace-tau
JP7397063B2 (ja) * 2018-08-16 2023-12-12 デナリ セラピューティクス インコーポレイテッド 操作された二重特異性タンパク質
AU2019326545A1 (en) * 2018-08-22 2021-03-11 Denali Therapeutics Inc. Anti-HER2 polypeptides and methods of use thereof
TW202100550A (zh) 2019-03-03 2021-01-01 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體
CA3140201A1 (fr) * 2019-05-31 2020-12-03 Xiyun CHAI Composes et procedes ciblant la proteine tau humaine
GB2585252A (en) * 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
KR20220130678A (ko) 2019-12-23 2022-09-27 데날리 테라퓨틱스 인크. 프로그라눌린 변이체들
JP2023508596A (ja) 2020-01-02 2023-03-02 エフ． ホフマン－ラ ロシュ アーゲー 脳内の治療用抗体の量を決定するための方法
BR112022013756A2 (pt) * 2020-01-13 2022-10-11 Denali Therapeutics Inc Anticorpos anti-trem2 e métodos de uso dos mesmos
EP4229192A1 (fr) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées
WO2023041805A1 (fr) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour l'amélioration de l'efficacité d'une thérapie par inhibiteur de hdac et la prédiction de la réponse à un traitement comprenant un inhibiteur de hdac
WO2024133723A1 (fr) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Méthodes permettant de diminuer la résistance thérapeutique acquise à la chimiothérapie et/ou à la radiothérapie

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008302A1 (fr) * 1991-10-25 1993-04-29 Itt Automotive Europe Gmbh Anticorps monoclonaux diriges contre la proteine tau associee aux microtubules
JP4393382B2 (ja) 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
WO2005062977A2 (fr) 2003-12-23 2005-07-14 The Regents Of The University Of California Anticorps humains d'internalisation specifiques du cancer de la prostate
AU2005245785B2 (en) 2004-04-15 2011-04-07 Banyan Biomarkers Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
US7435804B2 (en) * 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b
BRPI0708970A2 (pt) 2006-03-21 2011-06-21 Wyeth Corp método para o tratamento de um sujeito com uma doença ou transtorno caracterizado por depósito amilóide de a-beta; método de inibição ou redução da acumulação de depósito amilóide de a-beta em um sujeito; método de inibição ou redução da neurodegeneração em um sujeito; e método de inibição ou redução do declìnio cognitivo, ou de melhora da cognição, em um sujeito
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
SG177954A1 (en) 2007-01-05 2012-02-28 Univ Zuerich Method of providing disease-specific binding molecules and targets
US9272030B2 (en) 2007-10-17 2016-03-01 Janssen Sciences Ireland Uc Use of tau to monitor immunotherapy
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
JP2012528117A (ja) 2009-05-28 2012-11-12 グラクソ グループ リミテッド 幹細胞の標的化
EP4218794A3 (fr) * 2009-06-10 2023-09-13 New York University Ciblage immunologique de protéines tau pathologiques
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
WO2011026031A1 (fr) 2009-08-28 2011-03-03 The Board Of Regents Of The University Of Texas System Anticorps liant les oligomères de la protéine tau
WO2011032155A2 (fr) 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-arn, autoanticorps et marqueurs protéiques pour le diagnostic d'une lésion neuronale
CA2812865C (fr) 2010-10-07 2021-01-26 Ac Immune S.A. Anticorps phosphospecifiques reconnaissant la proteine tau
WO2012049570A1 (fr) 2010-10-11 2012-04-19 Panima Pharmaceuticals Ag Anticorps anti-tau humain
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
US9506051B2 (en) 2011-05-20 2016-11-29 Oligomerix, Inc. Tau protease compositions and methods of use
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
CA2837975C (fr) 2011-08-23 2022-04-05 Roche Glycart Ag Molecules bispecifiques de liaison a l'antigene activant les lymphocytes t.
CN109265543B (zh) 2011-09-19 2022-04-26 阿克松神经系统科学公司 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断
CN104080806B (zh) 2011-10-07 2018-01-19 Ac免疫有限公司 识别Tau的磷酸化特异抗体
SI2794654T1 (sl) 2011-12-20 2019-08-30 Janssen Biotech, Inc. Protitelesa proti PHF-tau njihove uporabe
EP2834270B1 (fr) 2012-04-05 2019-10-30 AC Immune S.A. Anticorps tau humanisé
TWI700296B (zh) 2012-05-31 2020-08-01 公立大學法人大阪市立大學 失智症治療劑或預防劑
WO2014008404A1 (fr) * 2012-07-03 2014-01-09 Washington University Anticorps dirigés contre tau
US9567395B2 (en) 2012-08-16 2017-02-14 Ipierian, Inc. Methods of treating a tauopathy
US9650436B2 (en) 2012-10-12 2017-05-16 Arizona Board Of Regents On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
LT2935326T (lt) 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
SG11201506244VA (en) 2013-03-13 2015-09-29 Prothena Biosciences Ltd Tau immunotherapy
RU2661111C2 (ru) 2013-03-15 2018-07-11 Ац Иммуне С.А. Антитела к тау и способы применения
JP6448614B2 (ja) 2013-03-15 2019-01-09 ベス イスラエル デアコネス メディカル センター インコーポレイテッド コンフォメーション特異的抗体の発生および使用のための方法および組成物
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
EP3041865A2 (fr) 2013-09-03 2016-07-13 NovImmune S.A. Molécules de liaison bispécifiques facilement isolées au format natif, mais possédant des régions constantes mutées
JP6629201B2 (ja) 2013-11-27 2020-01-15 アイピエリアン，インコーポレイティド タウオパチーの処置方法
US20160333063A1 (en) 2013-12-13 2016-11-17 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof
CA2932958A1 (fr) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Anticorps anti-tau(ps422) humanises et leurs methodes d'utilisation
EP2899208A1 (fr) 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Anticorps à domaine unique de camélidés dirigés contre des protéines tau phosphorylées et procédés de production de conjugués de ceux-ci
CA2938152A1 (fr) 2014-02-10 2015-08-13 Merck Sharp & Dohme Corp. Anticorps qui se lient a la proteine tau humaine et dosage pour quantifier la proteine tau humaine au moyen des anticorps
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
SG11201606824VA (en) 2014-02-19 2016-09-29 Hoffmann La Roche Blood brain barrier shuttle
US10400034B2 (en) 2014-06-26 2019-09-03 Janssen Vaccines & Prevention, B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
CN107073297B (zh) 2014-07-08 2021-09-14 纽约大学 Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
DE102014013571A1 (de) 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoklonaler Antikörper gegen humanes TAU-Protein
CA3001724A1 (fr) 2014-10-10 2016-04-14 National Research Council Of Canada Anticorps anti-tau et ses utilisations
US10323082B2 (en) 2014-10-14 2019-06-18 The Research Foundation For Mental Hygiene, Inc. Treatment of tauopathies by passive immunization targeting the N-terminal projection domain of tau
RU2730668C2 (ru) 2014-11-19 2020-08-24 Аксон Ньюросайенс Се Гуманизированные тау-антитела при болезни альцгеймера
WO2016112078A2 (fr) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anticorps tau/anti-phf et leurs utilisations
MA41451A (fr) 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
EP3261670A4 (fr) 2015-02-24 2018-08-01 Rpeptide, LLC Anticorps anti-tau
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
AU2016270858B2 (en) * 2015-06-05 2022-04-28 Ac Immune Sa Anti-Tau antibodies and methods of use
PL3313877T3 (pl) 2015-06-24 2020-11-02 F. Hoffmann-La Roche Ag Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
CN108282997B (zh) 2015-06-25 2020-12-25 肌肉骨骼科学教育研究所有限公司 用于植入的椎间融合装置和系统
CA2991264C (fr) 2015-07-06 2023-10-10 Ucb Biopharma Sprl Anticorps se liant a tau
UA124616C2 (uk) 2015-07-06 2021-10-20 Юсб Біофарма Срл Зв'язуюче тау-білок антитіло
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US20200079825A1 (en) 2015-07-13 2020-03-12 The General Hostital Corporation Rare phosphorylated high molecular weight (hmw) tau species that are involved in neuronal uptake and propagation and applications thereof
FI3334761T3 (fi) 2015-08-13 2023-08-14 Univ New York Vasta-ainepohjaisia molekyylejä, jotka ovat selektiivisiä Taun {p}Ser404-epitoopille, ja niiden käyttöjä tauopatian diagnosoinnissa ja hoidossa
JP6913078B2 (ja) 2015-08-13 2021-08-04 ニューヨーク・ユニバーシティ タウの短縮型Ａｓｐ４２１エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用
SG10201912150TA (en) 2015-10-06 2020-02-27 Alector Llc Anti-trem2 antibodies and methods of use thereof
US20170138400A1 (en) 2015-11-12 2017-05-18 Schaeffler Technologies AG & Co. KG Bainite hardened stack bearing
WO2017100632A1 (fr) 2015-12-11 2017-06-15 Arizona Board Of Regents On Behalf Of Arizona State University Variants tau associés à la maladie d'alzheimer et aux lésions cérébrales traumatiques chez l'humain utilisés en tant que biomarqueurs et leurs méthodes d'utilisation
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
DK3452507T3 (da) 2016-05-02 2022-11-14 Prothena Biosciences Ltd Tau-immunoterapi
BR112018072389A2 (pt) 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem tau
WO2017194589A1 (fr) 2016-05-10 2017-11-16 Vib Vzw Inhibition du dysfonctionnement synaptique précoce à médiation par tau
PE20190227A1 (es) 2016-07-12 2019-02-13 H Lundbeck As Anticuerpos especificos para la tau hiperfosforilada y sus metodos de uso
WO2018017370A1 (fr) 2016-07-20 2018-01-25 Anahit Ghochikyan Anticorps anti-tau humanisés, compositions et procédés de fabrication et méthodes d'utilisation dans le traitement, le diagnostic et la surveillance de tauopathies
WO2018018031A1 (fr) 2016-07-22 2018-01-25 New York University Murine spécifique et anticorps monoclonaux humanisés détectant des changements de structure secondaire associés à une pathologie dans des protéines et des peptides
CA3032692A1 (fr) 2016-08-09 2018-02-15 Eli Lilly And Company Polytherapie a base d'anticorps pour le traitement de maladies neurodegeneratives
WO2018049219A1 (fr) 2016-09-08 2018-03-15 Regenerative Research Foundation Polypeptides anti-tau bi-fonctionnels et leur utilisation
FR3058143B1 (fr) 2016-10-27 2021-03-12 Univ Grenoble Alpes Nanocorps anti-tau
WO2018085653A1 (fr) 2016-11-04 2018-05-11 The Regents Of The University Of California Compositions ciblant la protéine tau à triple répétition pour le traitement de troubles neurodégénératifs, et leurs procédés de fabrication et d'utilisation
US9914781B1 (en) * 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
TW202328181A (zh) 2016-12-07 2023-07-16 美商建南德克公司 抗-tau抗體及使用方法
US10995137B2 (en) 2017-01-04 2021-05-04 H. Lundbeck A/S Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
US11249093B2 (en) 2017-03-28 2022-02-15 Janssen Vaccines & Prevention B.V. Methods for detection of Tau protein aggregation modulating compounds
EA201992281A1 (ru) 2017-03-28 2020-02-13 Янссен Вэксинс Энд Превеншн Б.В. Связывающие молекулы, специфично связывающиеся с тау-белком
TW202400231A (zh) 2017-03-28 2024-01-01 美商建南德克公司 治療神經退化性疾病之方法
WO2018178078A1 (fr) 2017-03-28 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouvelle espèce tau
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
CA3064550A1 (fr) 2017-06-16 2018-12-20 Bristol-Myers Squibb Company Compositions et methodes de traitement de tauopathies
US10662246B2 (en) 2017-07-10 2020-05-26 New York University Monoclonal antibody to treat alzheimer's disease, prion disease, frontotemporal dementias and traumatic brain injury/chronic traumatic encephalopathy
US20210154184A1 (en) 2017-07-12 2021-05-27 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
BR112020001922A2 (pt) 2017-08-01 2020-08-04 Amgen Inc. sistemas e métodos para realização de um ensaio de glicanas em tempo real de uma amostra
KR102225178B1 (ko) 2017-10-16 2021-03-10 에자이 알앤드디 매니지먼트 가부시키가이샤 항-타우 항체 및 그의 용도
WO2019094576A1 (fr) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anticorps bispécifiques bace-tau

Also Published As

Publication number Publication date
AU2018221049A1 (en) 2019-09-19
EP3583123A1 (fr) 2019-12-25
CA3053379A1 (fr) 2018-08-23
CN110520440A (zh) 2019-11-29
MA47499A (fr) 2019-12-25
MX2019009817A (es) 2019-11-21
US11370832B2 (en) 2022-06-28
TW201843175A (zh) 2018-12-16
BR112019017021A2 (pt) 2020-04-14
WO2018152359A1 (fr) 2018-08-23
IL268658A (en) 2019-10-31
JP2020508054A (ja) 2020-03-19
US20200216522A1 (en) 2020-07-09
KR20190134997A (ko) 2019-12-05

Similar Documents

Publication Publication Date Title
SG11201907422RA (en) Anti-tau antibodies and methods of use thereof
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201907419PA (en) Transferrin receptor transgenic models
SG11201901548SA (en) Anti-tim-3 antibodies and use thereof
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201804178YA (en) Pd1 and/or lag3 binders
SG11201811424PA (en) Mirrored token vault
SG11201903693QA (en) Polypeptide variants and uses thereof
SG11201908051RA (en) Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201809620UA (en) The contorsbody - a single chain target binder
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201810887UA (en) Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
SG11201809789SA (en) Dna monoclonal antibodies targeting checkpoint molecules
SG11201804856VA (en) C-terminal lysine conjugated immunoglobulins
SG11201909048TA (en) Use of klk5 antagonists for treatment of a disease